Discover the latest in health: evidence‑based wellness tips, medical breakthroughs, nutrition guidance, fitness insights, and expert advice for a healthier, happier life.
Hims & Hers, the telehealth company known for direct-to-consumer healthcare products, is navigating a complex legal and regulatory landscape surrounding its provision of compounded weight loss medications. The company is facing increased pressure from both federal regulators and the manufacturer of popular weight loss drugs, Novo Nordisk, as concerns mount over the safety and legality of these compounded alternatives.
The core of the issue lies in Hims & Hers’ offering of compounded versions of drugs like semaglutide, the active ingredient in Novo Nordisk’s Wegovy and Ozempic. Compounding pharmacies create customized medications by combining ingredients, often used to address shortages or provide alternative formulations. However, the practice has approach under scrutiny when used to replicate patented drugs, particularly those in high demand like GLP-1 receptor agonists used for weight loss. The increasing popularity of these drugs has led to supply challenges, prompting some patients to seek alternatives through companies like Hims & Hers.
In early February 2026, Hims & Hers announced it would cease sales of a specific compounded version of a weight loss pill after facing regulatory challenges, as reported by The Latest York Times. This move came amid legal action and concerns raised by Novo Nordisk regarding the unauthorized replication of its patented medication. The company had been offering a cheaper alternative, but the legal challenges proved unsustainable.
The company continues to offer access to injectable GLP-1 medications, aiming to pass cost savings onto customers, according to a May 20, 2024, press release. Hims & Hers emphasizes its holistic weight loss program, focusing on personalized and affordable care. However, the apply of compounded drugs remains a point of contention.
The Hill reported just four days ago that Hims & Hers is currently battling both federal regulators and Novo Nordisk over its sale of these compounded weight loss drugs, as detailed in an article on February 19, 2026. The legal battles center on whether the compounded drugs infringe on Novo Nordisk’s patents and whether they meet the necessary safety standards.
The Food and Drug Administration (FDA) has been increasing its oversight of compounding pharmacies in recent years, particularly those involved in the production of complex medications like GLP-1 receptor agonists. Concerns exist about the quality control and consistency of compounded drugs, as they are not subject to the same rigorous review process as FDA-approved medications.
Hims & Hers maintains that it provides a valuable service by offering affordable access to weight loss medications for individuals who may struggle to obtain them through traditional channels. The company similarly offers other telehealth services, including treatments for hair loss, erectile dysfunction, and mental health, as highlighted on its website, Hims and Hers.
The situation raises broader questions about the regulation of compounding pharmacies and the balance between patient access, affordability, and drug safety. As demand for weight loss medications continues to rise, the debate over compounded drugs is likely to intensify. The outcome of the legal battles facing Hims & Hers could set a precedent for the industry and shape the future of access to these medications.
Looking ahead, the resolution of the legal challenges and the evolving regulatory landscape will be critical for Hims & Hers. The company’s ability to navigate these hurdles will determine its continued role in the weight loss medication market. Further developments from the FDA and Novo Nordisk are expected in the coming months, potentially impacting the availability and cost of these medications for patients.
Have your say: What impact do you believe increased regulation of compounding pharmacies will have on patient access to medications?
Disclaimer: This article provides informational content only and is not intended to be a substitute for professional medical advice. Always consult with a qualified healthcare provider for any questions you may have regarding your health or treatment.